Skip to main content

$0.315 0.010 (3.28%)

High

$0.32

Low

$0.30

Trades

243

Turnover

$627,825

Volume

2,012,212
30 June 2023 at 4:10pm
Register to track IMM and receive email alerts.

Efti to be evaluated in new triple combination therapy trial

StockBot

416,823 posts

IMM released this announcement to the ASX on 21 June 2021, 9:48. The announcement is marked as price sensitive, and is 2 page(s) in length and 230.43kb in size.

You can view all announcements from IMM and see how they appear on a price chart on the announcements page.

At the date of this announcement, IMM was 0.460% short sold according to ASIC data. It was ranked the 280th most shorted stock on the ASX. It is now ranked as the 138th most shorted stock on the ASX with 1.859% of total shares short sold as of the latest reported data (19 June 2025).

Other Recent Announcements from IMM
Application for quotation of securities - IMM 29 June 2023, 10:09
US patent granted for Efti with PD-1 pathway inhibitor 27 June 2023, 14:37
Immutep completes underwritten retail entitlement offer 27 June 2023, 8:16
Efti to be evaluated in new triple combination therapy trial 21 June 2021, 9:48
Proposed issue of securities - IMM 21 June 2021, 9:48
Immutep Capital Raising Presentation 21 June 2021, 9:47
Immutep secures commitments for A$60 million in a Placement 21 June 2021, 9:47
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track IMM and receive email alerts.